Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.41 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 4/20 | 0.41 |
| ▸ | CMA1 | P23946 | 1/20 | 0.40 |
| ▸ | TDP2 | O95551 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 1/20 | 0.37 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25757905 | 0.79 | PARP10 (0.41) | GAAPARP10PARP11PARP1MEN1 | |
| SCHEMBL6128272 | 0.79 | MEN1 (0.36) | EGFRGAANPSR1MEN1MAPT | |
| SCHEMBL6128309 | 0.76 | ALDH1A1 (0.43) | GAANPSR1MEN1MAPTKMT2A | |
| SCHEMBL6128344 | 0.75 | CA12 (0.38) | EGFRMEN1MAPTKMT2A | |
| SCHEMBL10060233 | 0.75 | PARP1 (0.44) | EGFRLMNANPSR1PARP1MEN1 | |
| SCHEMBL30325558 | 0.73 | MAPT (0.36) | EGFRGAANPSR1PNMTMEN1 | |
| SCHEMBL11195016 | 0.73 | GAA (0.60) | EGFRGAANPSR1PARP1MEN1 | |
| SCHEMBL147262 | 0.73 | GAA (0.60) | EGFRGAANPSR1PARP1MEN1 | |
| SCHEMBL16852147 | 0.72 | GAA (0.44) | EGFRLMNAGAAHIF1ANPSR1 | |
| SCHEMBL20821122 | 0.72 | ABCC4 (0.34) | MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202782-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2012-08-09 | — | — | US | disclosed |
| US-20120202782-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2012-08-09 | — | — | US | disclosed |
| US-20120202782-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2012-08-09 | — | — | US | disclosed |
| US-8178526-B2 | Compounds and compositions as ITPKb inhibitors | IRM LLC (BM) | 2012-05-15 | — | — | US | disclosed |
| US-8178526-B2 | Compounds and compositions as ITPKb inhibitors | IRM LLC (BM) | 2012-05-15 | — | — | US | disclosed |
| US-8178526-B2 | Compounds and compositions as ITPKb inhibitors | IRM LLC (BM) | 2012-05-15 | — | — | US | disclosed |
| EP-2167498-B1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2010-09-15 | — | — | EP | disclosed |
| EP-2167498-B1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2010-09-15 | — | — | EP | disclosed |
| US-20100184748-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2010-07-22 | — | — | US | disclosed |
| US-20100184748-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2010-07-22 | — | — | US | disclosed |
| US-20100184748-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2010-07-22 | — | — | US | disclosed |
| EP-2167498-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008157210-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008157210-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202782-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IP6K1, IP6K2, IP6K3 | EGFR 3652/4885LMNA 2876/4885GAA 2152/4885 |
| US-20100184748-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IP6K1, IP6K3, IP6K2 | EGFR 3732/4885LMNA 3015/4885GAA 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.